SCHEMBL280066

SCHEMBL280066

NNC(=O)c1ccc(C(=O)NNc2ccccn2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 7/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NPC1 O15118 5/20 0.51
RAB9A P51151 5/20 0.51
MITF O75030 1/20 0.51
KMT2A Q03164 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
HPGD P15428 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279991 0.83 GAA (0.52) GAASMN1; SMN2NPC1RAB9AMITF
SCHEMBL14395985 0.81 GAA (0.50) GAASMN1; SMN2NPC1RAB9AMITF
SCHEMBL13006697 0.80 GAA (0.49) GAASMN1; SMN2NPC1RAB9AMITF
SCHEMBL25234792 0.77 GAA (0.56) GAASMN1; SMN2NPC1RAB9AMITF
SCHEMBL10989725 0.77 GAA (0.55) GAASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL1587891 0.75 HPGD (0.72) SMN1; SMN2NPC1RAB9AKMT2AL3MBTL1
SCHEMBL6972046 0.75 HDAC1 (0.77) NPC1RAB9AHDAC3HDAC4HDAC1
SCHEMBL276955 0.74 ALDH1A1 (0.58) GAAKMT2AL3MBTL1ALDH1A1HDAC3
SCHEMBL13385745 0.73 GAA (0.66) GAASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL29995352 0.73 SMN1; SMN2 (0.61) GAASMN1; SMN2NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL GAA 2220/4885SMN1; SMN2 1437/4885NPC1 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.